- Home
- EMD vs ARVN Comparison
EMD vs ARVN Comparison
Compare EMD & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMD | ARVN |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 626.1M | 658.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | EMD | ARVN |
|---|---|---|
| Price | $10.43 | $8.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $15.05 |
| AVG Volume (30 Days) | 194.4K | ★ 780.8K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.41 | $6.06 |
| 52 Week High | $11.30 | $14.22 |
Technical Indicators
Market Signals| Indicator | EMD | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 29.09 |
| Support Level | $10.18 | $7.35 |
| Resistance Level | $10.57 | $10.18 |
| Average True Range (ATR) | 0.17 | 0.66 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 5.26 | 2.44 |
Price Performance
Historical ComparisonAbout EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management and long term investment company. The primary investment objective of the company is to seek high current income, and the secondary objective is to seek capital appreciation.
About ARVN Arvinas Inc.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.